Status:
COMPLETED
Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
FEMALE
50-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is compare treatment with valsartan with the possible addition of a diuretic, hydrochlorothiazide, on high blood pressure with the drug amlodipine with the possible addition ...
Eligibility Criteria
Inclusion
- Postmenopausal women
- Mild to moderate hypertension
- Statin therapy or LDL≤ 4.1 mmol/L
Exclusion
- Severe hypertension
- LDL \> 4.1 mmol/L if not taking anti-hyperlipidemic medication
- Certain hormonal therapy
- History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
- Liver, kidney, or pancreas disease
- Diabetes
- Raynaud's disease or any other significant peripheral vascular disease
- Allergy to certain medications used to treat high blood pressure
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT00171054
Start Date
September 1 2003
End Date
October 1 2007
Last Update
June 6 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Basel, Switzerland